Rheonix Inc. Receives FDA Emergency Use Authorization for Rapid, Fully Automated Molecular COVID-19 Test
Sample-to-answer method will enable rapid testing in distributed locations
Read Press Release
Read Letter of Authorization
Mayor Richard C. David on Thursday joined John Carrigg, President and CEO of United Health Services (UHS), and Gregory J. Galvin, Ph.D., President and CEO of Rheonix Inc., to announce a same-day COVID-19 virus testing partnership between the City of Binghamton and United Health Services.
Read More »
Cayuga Medical Center to be First Hospital in NY State to Use This New Technology
Read More »
ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular diagnostics solutions, has been granted patent 8,852,919 “Microfluidic Apparatus, Method, and Applications” for its automated molecular system, the EncompassMDx™. This recent patent will help researchers and clinicians analyze tissue samples preserved in paraffin more efficiently, at a lower cost and with higher processing throughput.
The ‘919 patent automates a liquid-liquid extraction process that easily removes paraffin from preserved tissue samples… Read More »
ITHACA, N.Y. — Rheonix, Inc., a developer of fully automated molecular testing solutions, will be presenting at the inaugural BTIG Emerging Technologies in Healthcare Diagnostics symposium. Richard Montagna, Ph.D., senior vice president for Scientific and Clinical Affairs at Rheonix, will speak about genomic workflow innovation and discuss the company’s breakthrough innovation utilizing a proprietary liquid-liquid extraction methodology for automated preparation of paraffin-preserved tissue samples for nucleic acid analysis.
Dr. Montagna’s comments… Read More »
BUFFALO, N.Y.— The University at Buffalo’s New York State Center of Excellence in Bioinformatics & Life Sciences (CBLS) will host Rheonix, Inc., a molecular diagnostic company based in Ithaca, N.Y., to deliver September’s Life Sciences Commercialization Lecture.
The lecture will take place on Sept. 18 from 4 to 5 p.m. in the Bruce A. Holm Commons area (2nd floor), at the CBLS, 701 Ellicott Street, Buffalo.
Senior Vice President for Scientific and… Read More »
ITHACA, N.Y. — Rheonix, Inc., a developer of fully automated molecular testing solutions, recently spoke at Beijing University of Chemical Technology, School of Information and Technology. Dr. Zongyuan Chen, senior research engineer at Rheonix, lectured on the in vitro diagnostics (IVD) market to an audience of 70 graduate students and faculty members and provided an in-depth look at Rheonix’s breakthrough platform, the EncompassMDx™. According to IVD Technology magazine, the U.S.… Read More »
ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular testing solutions, will address the need for access to critical advanced molecular testing, labor shortages that limit the availability of testing, and other obstacles laboratories face in adopting this technology at the American Association for Clinical Chemistry (AACC) Annual Meeting in Chicago, Illinois, July 27-31.
Rheonix will display its Chemical and Reagent Device (CARD) and EncompassMDx™ molecular testing platform. The… Read More »
Food poisoning. The impact on consumers can range from an inconvenient bout of gastrointestinal discomfort to hospitalization or even death. Every year in the U.S., one in six people suffers a food-related illness. Foodborne pathogens were responsible for 3,000 deaths reported in the U.S. in 2013. To help protect consumers, food producers and manufacturers follow rules promulgated by the U.S. Food and Drug Administration (FDA) and test food for pathogens.… Read More »
ITHACA, N.Y. — Rheonix, Inc., a developer of fully automated molecular testing solutions, has received a Small Business Innovation Research (SBIR) Phase I Fast-Track grant from the National Institutes of Health (NIH) to complete the development of a fully automated self-confirming assay that can simultaneously detect HIV/AIDS antibodies and viral RNA in a single specimen. The Rheonix system will simplify HIV testing and eliminate the need for multiple patient visits… Read More »
ITHACA, N.Y. — Richard A. Montagna, Ph.D., senior vice president for scientific and clinical affairs at Rheonix Inc., a developer of fully automated molecular diagnostics solutions, has been accepted as a Fellow of the National Academy of Clinical Biochemistry (NACB).
Fellowship in NACB is open to members of the American Association of Clinical Chemistry (AACC) who are doctoral-level clinical scientists. Fellows must hold American Board of Clinical Chemistry or equivalent board… Read More »
ITHACA, N.Y. – March 24, 2014 - Rheonix, Inc., a developer of fully automated molecular testing solutions, announced today that it has been invited to exhibit at “The Future of In-Vitro Diagnostics.” The exclusive conference, held April 10, 2014 in Menlo Park/Palo Alto, CA, is hosted by Siemens Venture Capital, the investment arm of Siemens, and Siemens Healthcare.
The fifth annual conference brings together over 100 CEOs and CTOs, investors, key… Read More »
ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular diagnostics solutions, has been granted six additional patents for its core microfluidic device, the Chemistry and Reagent Device, or CARD® . One patent was issued Feb. 11, while the other five have been allowed but not yet issued.
The Rheonix CARD is a disposable cartridge the size of a credit card that runs multiple samples simultaneously without user intervention. Once… Read More »